Douglas Lane & Associates LLC Purchases 298,715 Shares of Moderna, Inc. (NASDAQ:MRNA)

Douglas Lane & Associates LLC boosted its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 62.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 773,804 shares of the company’s stock after acquiring an additional 298,715 shares during the period. Douglas Lane & Associates LLC’s holdings in Moderna were worth $32,175,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently modified their holdings of the business. State Street Corp raised its holdings in shares of Moderna by 12.1% during the third quarter. State Street Corp now owns 16,847,212 shares of the company’s stock worth $1,125,899,000 after acquiring an additional 1,823,276 shares during the period. Geode Capital Management LLC boosted its position in shares of Moderna by 2.6% during the third quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company’s stock worth $470,670,000 after buying an additional 178,115 shares during the period. Wellington Management Group LLP grew its holdings in shares of Moderna by 21.0% during the third quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock worth $349,166,000 after buying an additional 906,114 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Moderna by 0.5% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,890,812 shares of the company’s stock valued at $260,023,000 after buying an additional 19,819 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its position in Moderna by 6.2% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 3,073,934 shares of the company’s stock worth $205,431,000 after acquiring an additional 178,939 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Insiders Place Their Bets

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the company’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the transaction, the insider now owns 19,717 shares in the company, valued at approximately $843,690.43. This represents a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last quarter, insiders have sold 2,664 shares of company stock valued at $115,210. Insiders own 15.70% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have commented on MRNA shares. Royal Bank of Canada reissued a “sector perform” rating and set a $75.00 price target on shares of Moderna in a research report on Thursday, September 19th. Bank of America reissued an “underperform” rating and issued a $41.00 target price on shares of Moderna in a research note on Tuesday, December 10th. HSBC raised shares of Moderna from a “hold” rating to a “buy” rating and set a $58.00 price target on the stock in a research report on Monday, November 18th. Oppenheimer lowered shares of Moderna from an “outperform” rating to a “market perform” rating in a research note on Friday, September 13th. Finally, Barclays cut their price target on Moderna from $125.00 to $111.00 and set an “overweight” rating for the company in a report on Friday, November 8th. Four investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Moderna has a consensus rating of “Hold” and a consensus target price of $78.83.

Moderna Stock Down 8.3 %

NASDAQ MRNA traded down $3.95 during trading hours on Wednesday, hitting $43.58. The company’s stock had a trading volume of 9,826,371 shares, compared to its average volume of 10,336,079. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. The company’s 50-day simple moving average is $43.22 and its two-hundred day simple moving average is $70.88. The company has a market capitalization of $16.77 billion, a PE ratio of -7.49 and a beta of 1.60. Moderna, Inc. has a 52 week low of $35.80 and a 52 week high of $170.47.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.89) by $1.92. The firm had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The business’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.39) EPS. Research analysts anticipate that Moderna, Inc. will post -9.3 EPS for the current fiscal year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.